Research To Practice | Oncology Videos

Proceedings from a live event on April 11, 2026, held during the 2026 SGO Annual Meeting on Women's Cancer and moderated by Dr Ritu Salani, including the following topics: Biology of Advanced Endometrial Cancer (EC); Optimal Approach to Biomarker Assessment in Patients with Newly Diagnosed Disease — Dr Backes (0:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced EC — Dr Powell (25:18) Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy in Advanced EC — Dr Salani (59:02) CME information and select publications

Featuring an interview with Dr Nikhil I Khushalani, including the following topics: Overview of nonmelanoma skin cancers (0:00) Systemic therapy for nonmelanoma skin cancers (12:11) Immune checkpoint inhibitors for special patient populations (20:30) Hedgehog inhibitors for basal cell carcinoma (32:14) New developments in therapy for nonmelanoma skin cancers (38:52) Case: A man in his early 70s with cutaneous squamous cell carcinoma receives cemiplimab (43:41) Case: A man in his mid 70s with a history of basal cell carcinoma presents with disease of the ocular surface and receives immunotherapy (51:50) Case: A man in his early 70s with recurrent metastatic basal cell carcinoma receives vismodegib followed by cemiplimab on disease progression (57:22) CME information and select publications

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00) Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal cancer (8:58) Approach to managing Stage III colon cancer with ctDNA-positive results after adjuvant treatment (13:35) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 2: Future Directions in the Use of Oral SERDs for HR-Positive, HER2-Negative BC — Erica Mayer, MD, MPH, FASCO CME information and select publications

Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics: Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00) Second-Line Treatment for Metastatic Breast Cancer (16:01) First-Line Therapy for Metastatic Disease (33:19) Adjuvant Therapy (35:26) Toxicity, Quality of Life (47:59) New Directions (55:22) CME information and select publications

Featuring perspectives from Dr Suresh S Ramalingam and Dr Helena Yu, including the following topics: Introduction: Genomics of EGFR (and HER2) (0:00) Metastatic Disease (9:30) Localized Disease (30:22) EGFR Exon 20 Insertion Mutations (46:57) New Agents (54:20) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR-Mutant NSCLC (eg, Nonmetastatic Disease, Exon 20 Insertion Mutations, Novel Agents) — Suresh S Ramalingam, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) — Helena Yu, MD CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME information and select publications

Featuring perspectives from Dr Andrew J Armstrong and Dr Scott T Tagawa, including the following topics: Introduction: Evolution of the Prostate Cancer Model; Prostate Cancer Working Group 4 (PCWG4) (0:00) Hormonal Therapy (5:48) Chemotherapy (Docetaxel) (26:38) PARP Inhibition (29:49) Radioligand Therapy (36:56) New Agents (43:37) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Scott T Tagawa, MD, MS CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Andrew J Armstrong, MD, ScM CME information and select publications

Featuring perspectives from Dr Amir Fathi and Dr Eunice S Wang, including the following topics: Introduction: Overview — Biopharmacologic Considerations (0:00) Menin Inhibitor Monotherapy (21:51) Differentiation Syndrome (36:12) Menin Inhibitor Combination Approaches (45:15) Future Directions (49:59) PARADIGM — Randomized Phase II Trial (53:24) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 1: Biology Underlying the Utility of Menin Inhibitors in Acute Leukemias: Use of These Agents as Monotherapy — Eunice S Wang, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 2: Potential Role of Menin Inhibitors as a Component of Combination Therapy — Amir Fathi, MD CME information and select publications

Featuring an interview with Dr Natalie Vokes, including the following topics: Perioperative minimal residual disease (MRD) detected by circulating tumor DNA (ctDNA) testing in patients with lung cancer (0:00) Ohara S et al. Clinical significance of perioperative MRD detected by ctDNA in patients with lung cancer with a long follow-up data: An exploratory study. JTO Clin Res Rep 2024;6(3):100762. Abstract Masuda K et al. MRDSEEKER (JCOG2111A): A prospective study to evaluate MRD and its association with prognosis in curative-intent NSCLC. World Conference on Lung Cancer 2025;Abstract P3.18.04.  Zhou C et al. IMpower010: Biomarkers of disease-free survival in a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. ESMO IO 2021;Abstract 2O. MRD analysis of adjuvant therapy with osimertinib for resected EGFR-mutated Stage IB to IIIA non-small cell lung cancer (NSCLC) (8:28) Herbst RS et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med 2025;31(6):1958-68. Abstract MRD analyses of perioperative chemoimmunotherapy for resected NSCLC (15:12) Forde PM et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med 2025;393(8):741-52. Abstract  ctDNA dynamics in advanced NSCLC treated with immunotherapy (20:56) Vokes NI et al. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo). ASCO 2023;Abstract 9022. Anagnostou V et al. ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results. Nat Med 2023;29(10):2559-69. Abstract Anagnostou V et al. A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36). ASCO 2025;Abstract TPS8669. CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics: Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00) Potential role of thymidine kinase testing in monitoring response to therapy (4:56) Interpretation of next-generation sequencing testing; use of targeted therapy (10:59) Phase III lidERA Breast Cancer trial and its implications for the use of giredestrant (14:19) Interpreting plots from the Guardant360® test; future applications of circulating tumor DNA (19:07) Toxicity surrounding use of agents targeting the PAM signaling pathway; treatment for patients with PAM pathway alterations and ESR1 mutations (25:15) Potential role of artificial intelligence in profiling biomarkers; comparative efficacy of first- and later-line use of CDK inhibitors (30:26) Case: A woman in her mid 60s diagnosed with hormone receptor (HR)-positive, HER2-low metastatic breast cancer experiences disease progression after 5 years despite letrozole/ribociclib and is found to have ESR1 mutations, treated sequentially with elacestrant then trastuzumab deruxtecan (39:10) Case: A woman in her mid 50s who previously received treatment for localized disease develops progressive metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer (45:31) Case: A woman in her late 70s with HR-positive, HER2-negative breast cancer who previously received treatment for localized disease is now diagnosed with progressive PTEN-deficient metastatic disease (51:36) Case: A woman in her early 70s with HR-positive, HER2-low metastatic breast cancer and bone metastases initially receives letrozole in combination with abemaciclib, then abemaciclib monotherapy (53:59) CME information and select publications

Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics: Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00) Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy (5:21) Methodologies for biomarker assessment in clinical practice: Novel platforms (13:56) Appropriate timing for assessment of ESR1 and PI3K pathway alterations (17:34) Evolving guidelines for routine biomarker evaluation (21:37) Implications of precision oncology clinical trials for future biomarker utility (25:07) Summary, key questions, future directions (33:09) CME information and select publications  

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics: Case: A woman in her early 60s with muscle-invasive bladder cancer experiences disease progression with lung metastasis after surgery and receives enfortumab vedotin (EV)/pembrolizumab (0:00) Case: A man in his mid 70s with metastatic urothelial bladder cancer (UBC) starts first-line EV/pembrolizumab with a partial response, and testing reveals HER2 IHC 3+ (10:58) Case: A man in his late 60s with progression of metastatic UBC after multiple lines of therapy for whom testing reveals HER2 IHC 3+ receives trastuzumab deruxtecan (19:18) CME information and select publications

Featuring perspectives from Dr Virginia F Borges and Dr Ian E Krop, including the following topics: Introduction: Biology of "Triple-Positive" Breast Cancer; Implications for Therapeutic Development (0:00) Cases from the GMO Survey (13:01) First-Line Therapy for Metastatic HER2-Positive Disease (20:01) Maintenance Therapy for HR-Positive, HER2-Positive Disease (30:03) Maintenance Therapy for HR-Negative, HER2-Positive Disease (46:30) Cases from the GMO Survey (50:00) CME information and select publications

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Adjuvant treatment planning for Stage II or III microsatellite instability-high colon cancer (0:00) Roles of circulating tumor DNA (ctDNA), POLE mutations and advanced age in adjuvant treatment planning (6:08) Role of ctDNA in adjuvant treatment planning for Stage III colon cancer (12:31) CME information and select publications

Featuring perspectives from Dr Paul G Richardson, including the following topics: EXCALIBER-RRMM: A Phase III trial of iberdomide, daratumumab and dexamethasone for relapsed/refractory multiple myeloma (0:00) Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract  Phase III SUCCESSOR-1 and SUCCESSOR-2 studies evaluating mezigdomide-based regimens for relapsed/refractory multiple myeloma (8:24) Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372. Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070.  EMN26: A Phase II study of maintenance therapy with iberdomide after autologous stem-cell transplantation for newly diagnosed multiple myeloma (13:34) van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101.  STOMP: A Phase I study of selinexor, mezigdomide and dexamethasone for patients with relapsed/refractory multiple myeloma who experienced relapse with or are ineligible for T-cell-redirecting therapy (24:53) Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results. ASH 2025;Abstract 4010.  CME information and select publications

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Gastroesophageal cancer (0:00) Recurrent colorectal cancer (5:43) Colorectal cancer with brain metastases (9:59) CME information and select publications

Featuring an interview with Dr Ravin Ratan, including the following topics: Case: A woman in her early 40s who develops intense nausea and vomiting and is diagnosed with a pelvic desmoid tumor elects surveillance and experiences spontaneous regression of the tumor (0:00) Case: A woman in her late 30s with a painful desmoid tumor in the right pelvic wall receives cryoablation because of concerns about ovarian function (6:49) Case: A woman in her early 40s with breast implants and multiple resections of breast desmoid tumors receives nirogacestat for 2 years with positive response but develops mucositis and Grade 1 asthenia and stops treatment (14:10) Case: A woman in her mid 30s with a history of gastric sleeve and endometriosis presents with a painful desmoid tumor in the left upper quadrant, receives nirogacestat with headaches and gastrointestinal symptoms that improve over time and experiences a decrease in tumor size (21:27) CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Older patient with metastatic claudin 18.2-positive gastroesophageal (GE) cancer (0:00) Management of nausea and vomiting with zolbetuximab for GE cancer (9:37) Younger patient with metastatic claudin 18.2-positive, PD-L1-positive GE cancer (15:34) CME information and select publications

Featuring slide presentations and related discussion from Dr Nikhil I Khushalani, Dr Soo J Park, Dr Vishal Anil Patel and Dr Evan Wuthrick, including the following topics: Introduction (0:00) Current Management of Localized, Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) (9:55) Case: A man in his early 70s with cSCC who previously underwent surgery and adjuvant therapy (32:39) Case: A man in his early 60s with cSCC who receives cemiplimab (54:45) Incorporation of Radiation Therapy into the Multidisciplinary Management of cSCC and Basal Cell Carcinoma (BCC) (1:04:24) Case: A man in his early 70s with cSCC who receives radiation therapy after a surgeon expresses concern about the risks of surgery (1:22:15) Case: A man in his late 80s with cSCC who is not a candidate for surgery (1:24:09) Evidence-Based Treatment Strategies for Patients with BCC (1:26:00) Case: A man in his mid sixties with BCC who receives sonidegib (1:36:49) Case: A man in his late 70s with BCC who receives vismodegib (1:38:32) Dermatologic Care for Patients with cSCC and BCC (1:45:09) CME information and select publications

Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Case: A man in his early 40s with chronic immune thrombocytopenia (ITP) receives romiplostim with rituximab — Bhavana (Tina) Bhatnagar, DO (0:00) Case: A woman in her early 80s with metastatic adenocarcinoma of the lung responds to carboplatin/pemetrexed/pembrolizumab but after 14 months of maintenance pembrolizumab presents with ITP — Susmitha Apuri, MD (6:48) Case: A man in his late 70s with a 30-year history of chronic ITP who received corticosteroids and rituximab now receives avatrombopag — Sunil Gandhi, MD (12:06) Case: A woman in her early 80s with multiple comorbidities and a long history of ITP presents with confusion and fluid retention due to exacerbated congestive heart failure and receives fostamatinib — Dr Bhatnagar (19:26) CME information and select publications

Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics: Introduction (0:00) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25) Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54) Tolerability and Other Practical Considerations with Capivasertib — Dr Heath (1:03:15) CME information and select publications

Featuring perspectives from Ms Jamie Carroll, Prof Giuseppe Curigliano, Dr Marie E McDonnell and Dr Hope S Rugo, including the following topics: Introduction: Use of On-Body Glucose Monitoring Devices (0:00) Overview of Breast Cancer and Diabetes (9:39) PI3K/AKT/mTOR Pathway and Glucose Metabolism (19:28) Case Presentations — Part 1 (26:02) Current Data with Alpelisib, Capivasertib and Inavolisib (43:51) Prevention and Management of Hyperglycemia (1:02:17) Case Presentations — Part 2 (1:10:24) CME information and select publications

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics: Case: A man in his mid 50s with metastatic recurrence of urothelial bladder cancer (UBC) after neoadjuvant cisplatin/gemcitabine receives first-line enfortumab vedotin (EV)/pembrolizumab (0:00) Case: A man in his early 50s with muscle-invasive bladder cancer (MIBC) receives adjuvant pembrolizumab, experiences disease progression and then receives EV monotherapy (12:33) Case: A man in his late 80s with recurrent metastatic UBC after pembrolizumab therapy for MIBC receives EV monotherapy at a reduced dose (24:07) CME information and select publications

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Neoadjuvant immunotherapy for localized rectal cancer (0:00) Surveillance in neoadjuvant immunotherapy for localized rectal cancer (8:14) Determining a treatment strategy for resectable colon cancer (12:35) CME information and select publications

Featuring perspectives from Dr Matthew D Galsky, Dr Shilpa Gupta, Dr Terence Friedlander and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Introduction (0:00) Optimal Use of Anti-PD-1/PD-L1 Antibodies in Non-Muscle-Invasive Bladder Cancer — Dr Friedlander (2:27) Evolving Management of Muscle-Invasive Bladder Cancer — Dr Gupta (33:30) Current and Future Role of Novel Intravesical Therapies in Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (1:01:56) Emerging Utility of Circulating Tumor DNA Evaluation in Nonmetastatic UBC — Dr Galsky (1:32:47) CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Younger patient with metastatic HER2-positive, PD-L1-positive gastric cancer (0:00) Older patient with metastatic HER2-positive gastroesophageal (GE) cancer (8:13) Clinical applications for zanidatamab in GE cancer (13:58) CME information and select publications

Featuring perspectives from Dr Paul G Richardson, including the following topics: Mechanism of action and pharmacology of cereblon E3 ligase modulators (0:00) Available efficacy data (4:54) Extramedullary disease (10:51) Side effects and toxicity (16:58) CME information and select publications

Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Case: A woman in her early 70s incidentally diagnosed with immune thrombocytopenia (ITP) experiences a suboptimal response to prednisone and IVIG — Bhavana (Tina) Bhatnagar, DO (0:00) Case: A man in his early 50s with a long history of ITP undergoes splenectomy — Neil Morganstein, MD (5:06) Case: A woman in her mid 50s with symptomatic iron-deficiency anemia who was found to have ITP has received corticosteroids, rituximab and IVIG — Jennifer Yannucci, MD (12:25) Case: A woman in her early 30s who previously received ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and autologous stem cell transplant for Hodgkin lymphoma is diagnosed with ITP 5 years later that is refractory to high-dose prednisone, IVIG and rituximab, then romiplostim — Priya Rudolph, MD, PhD (18:19) CME information and select publications

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Novel immune checkpoint inhibitors (0:00) Gastroesophageal junction cancer (7:36) Gastric cancer (14:52) CME information and select publications

Featuring an interview with Dr Lajos Pusztai, including the following topics: Circulating tumor DNA monitoring for patients with ER-positive, HER2-negative high-risk breast cancer during adjuvant endocrine therapy (0:00) Clinical performance of a whole-genome assay for predicting disease recurrence (5:52) Using circulating tumor DNA status to personalize CDK4/6 inhibitor therapy (12:46) Neoadjuvant and adjuvant therapy stratified by circulating tumor DNA status (21:11) Utility of circulating tumor DNA status in the management of metastatic breast cancer (24:55) CME information and select publications

Featuring an interview with Dr Ravin Ratan, including the following topics: Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors: Results from the Phase III DeFi trial (0:00) Onset and resolution of ovarian toxicity with nirogacestat treatment for desmoid tumors: Updated safety analyses from the DeFi trial (4:37) Subgroup analysis of the Phase II part of the RINGSIDE Phase II/III trial of varegacestat for desmoid tumors (7:39) Surgical management of desmoid tumors; cryotherapy in the treatment of extra-abdominal desmoid tumors (10:30) CME information and select publications

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Biliary tract cancer progressing on first-line therapy (0:00) Gallbladder cancer (5:01) Biliary tract cancer with multiple biomarker targets (8:52) CME information and select publications

Featuring an interview with Dr Bijal Shah, including the following topics: Advent and importance of blinatumomab in the therapeutic landscape of acute lymphoblastic leukemia (ALL) (0:00) Similarities and differences between bispecific T-cell engagers (BiTEs) and bispecific antibodies (5:51) Rationale underlying the development of surovatamig and MK-1045; benefits of blinatumomab for patients without detectable minimal residual disease (9:56) Extramedullary ALL, including in the CNS (13:32) Key principles in the development and use of surovatamig and MK-1045, including structural features and recent efficacy and safety findings (18:34) Ongoing immunotherapy trials for ALL, including studies of BiTEs and chimeric antigen receptor T-cell therapy (25:37) Case: A woman in her late 50s with newly diagnosed Philadelphia chromosome-positive B-cell ALL and multiple comorbidities (31:48) Case: A woman in her early 50s with newly diagnosed B-cell ALL, a TP53 mutation and significant extramedullary disease including the CNS (41:16) Case: A man in his early 50s with intermediate-risk B-cell ALL who receives surovatamig on a clinical trial (53:05) CME information and select publications

Featuring a slide presentation and related discussion from Dr Bijal Shah, including the following topics: Historical approaches to managing acute lymphoblastic leukemia, their limitations and present approaches to treatment (0:00) Mechanistic approach underlying blinatumomab; key clinical trial data and their implications (7:29) Mechanistic approaches underlying surovatamig and MK-1045; dosing and administration strategies with various bispecific T-cell engagers (23:27) Key clinical trial data with surovatamig; implications for practice (32:38) Key clinical trial data with MK-1045; implications for practice (39:02) Synthesizing and comparing data across subcutaneous blinatumomab, surovatamig and MK-1045 (42:36) CME information and select publications